% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Krner:906898,
author = {Körner, Jannis and Albani, Simone and Vishal Sudha
Bhagavath Eswaran and Röhl, Anna B and Rossetti, Giulia and
Lampert, Angelika},
title = {{S}odium channels and local anesthetics – old friends
with new perspectives},
journal = {Frontiers in pharmacology},
volume = {13},
issn = {1663-9812},
address = {Lausanne},
publisher = {Frontiers Media},
reportid = {FZJ-2022-01753},
pages = {837088},
year = {2022},
abstract = {The long history of local anesthetics (LAs) starts out in
the late 19th century when the content of coca plant leaves
was discovered to alleviate pain. Soon after, cocaine was
established and headed off to an infamous career as a
substance causing addiction. Today, LAs and related
substances—in modified form—are indispensable in our
clinical everyday life for pain relief during and after
minor and major surgery, and dental practices. In this
review, we elucidate on the interaction of modern LAs with
their main target, the voltage-gated sodium channel (Navs),
in the light of the recently published channel structures.
Knowledge of the 3D interaction sites of the drug with the
protein will allow to mechanistically substantiate the
comprehensive data available on LA gating modification. In
the 1970s it was suggested that LAs can enter the channel
pore from the lipid phase, which was quite prospective at
that time. Today we know from cryo-electron microscopy
structures and mutagenesis experiments, that indeed Navs
have side fenestrations facing the membrane, which are
likely the entrance for LAs to induce tonic block. In this
review, we will focus on the effects of LA binding on fast
inactivation and use-dependent inhibition in the light of
the proposed new allosteric mechanism of fast inactivation.
We will elaborate on subtype and species specificity and
provide insights into modelling approaches that will help
identify the exact molecular binding orientation, access
pathways and pharmacokinetics. With this comprehensive
overview, we will provide new perspectives in the use of the
drug, both clinically and as a tool for basic ion channel
research.},
cin = {IAS-5 / INM-9},
ddc = {610},
cid = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525) / DFG
project 291198853 - FOR 2518: Funktionale Dynamik von
Ionenkanälen und Transportern - DynIon -},
pid = {G:(DE-HGF)POF4-5252 / G:(GEPRIS)291198853},
typ = {PUB:(DE-HGF)16},
pubmed = {35418860},
UT = {WOS:000783551000001},
doi = {10.3389/fphar.2022.837088},
url = {https://juser.fz-juelich.de/record/906898},
}